To investigate the effects of evolocumab in addition to statin therapy on HPR rates and platelet reactivity in patients with atherosclerotic cardiovascular disease (ASCVD) and HPR while on clopidogrel treatment. Secondary aims will include the effects on cholesterol levels.

Patients will be randomly assigned to receive either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).